Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Icatibant Acetate
Therapeutic Area : Genetic Disease
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Alembic Pharma gets USFDA nod for generic injection to treat hereditary angioedema
Details : Firazyr (icatibant acetate) is a bradykinin B2 receptor antagonist indicated for treatment of acute attacks of hereditary angioedema (HAE) in adults 18 years of age & older.
Product Name : Firazyr
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 17, 2024
Lead Product(s) : Icatibant Acetate
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Icatibant Acetate
Therapeutic Area : Genetic Disease
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Aurobindo Pharma Gets U.S. FDA nod for Generic Icatibant Injection
Details : Icatibant injection, for subcutaneous is a bradykinin B2 receptor antagonist indicated for treatment of acute attacks of hereditary angioedema in adults 18 years of ageand older.
Product Name : Firazyr-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 16, 2023
Lead Product(s) : Icatibant Acetate
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Icatibant Acetate
Therapeutic Area : Genetic Disease
Study Phase : Approved FDF
Sponsor : AmbioPharm
Deal Size : Inapplicable
Deal Type : Inapplicable
Adalvo Announces Successful DCP Closure for Icatibant
Details : Icatibant, a complex injectable peptide product, forming part of high-value product, is an equivalent and more affordable version of Firazyr (Takeda/Shire), used used to treat a serious orphan disease, acute attacks of hereditary angioedema.
Product Name : Icatibant Acetate-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 28, 2021
Lead Product(s) : Icatibant Acetate
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Sponsor : AmbioPharm
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Icatibant Acetate
Therapeutic Area : Genetic Disease
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SAJAZIR™ is a bradykinin B2 receptor antagonist indicated for treatment of acute attacks of hereditary angioedema (HAE) in adults 18 years of age and older.
Product Name : Sajazir
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 28, 2021
Lead Product(s) : Icatibant Acetate
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Icatibant Acetate
Therapeutic Area : Genetic Disease
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : This marks Glenmark's first synthetic decapeptide Icatibant Injection approval and will be manufactured in their North American manufacturing facility based in Monroe, North Carolina.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 24, 2021
Lead Product(s) : Icatibant Acetate
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Icatibant Acetate,Dexamethasone
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Quantum Leap concludes Icatibant Portion of I-SPY COVID Trial
Details : The latest development comes after the Data Monitoring Committee recommended concluding the icatibant arm on enrolling 95 patients and the agent meeting the predefined futility criterion.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 15, 2021
Lead Product(s) : Icatibant Acetate,Dexamethasone
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Icatibant Acetate
Therapeutic Area : Genetic Disease
Study Phase : Approved FDF
Sponsor : Sandoz B2B
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Sandoz in-licensed Icatibant injection, a critical anti-inflammatory medicine used to treat acute attacks of hereditary angioedema, from Slayback Pharma. Deal allows Sandoz to further grow its injectable medicine portfolio and supply another important me...
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 28, 2021
Lead Product(s) : Icatibant Acetate
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Sponsor : Sandoz B2B
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Icatibant Acetate
Therapeutic Area : Genetic Disease
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Icatibant injection is therapeutically equivalent to Firazyr®, and supplied as a 3 mL prefilled, single-use syringe that is self-administered subcutaneously into the abdominal area.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 12, 2020
Lead Product(s) : Icatibant Acetate
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable